Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review

References

• Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–469.
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006 May 01;20(3):123–137.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008 May 01; 9(5):503–510.
   PubMed Web of Science ®Google Scholar
• Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol. 2006 Jan 01; 118(1):1–10.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–1799.
   PubMed Web of Science ®Google Scholar
• Melero I, Rouzaut A, Motz GT, et al. T-Cell and NK-Cell Infiltration into Solid Tumors: a Key Limiting Factor for Efficacious Cancer Immunotherapy. Cancer Discov. 2014;4(5):522.
   PubMed Web of Science ®Google Scholar
• Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016 Sep 01; 17(9):1025–1036.
   PubMed Web of Science ®Google Scholar
• Vitale M, Cantoni C, Pietra G, et al. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 2014 Jun 01; 44(6):1582–1592.
   PubMed Web of Science ®Google Scholar
• Mushtaq MU, Papadas A, Pagenkopf A, et al. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018;6(1):65.
   PubMedGoogle Scholar
• Hu W, Wang G, Huang D, et al. Cancer Immunotherapy Based on Natural Killer Cells: current Progress and New Opportunities. Front Immunol. 2019;10:1205.
   PubMed Web of Science ®Google Scholar
• Kalaitsidou M, Kueberuwa G, Schütt A, et al. CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy. 2015 Jun 01;7(5):487–497.
   PubMed Web of Science ®Google Scholar
• Qasim W. Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019 May 01; 94(S1):S50–S54.
   PubMedGoogle Scholar
• Gilham DE, Debets R, Pule M, et al. CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med. 2012;18(7):377–384.
   PubMed Web of Science ®Google Scholar
• Kalos M, Nazimuddin F, Finklestein J, et al. Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. Blood. 2013 Nov 15;122(21):163.
   Web of Science ®Google Scholar
• Couzin-Frankel J. Supply of promising T cell therapy is strained. Science. 2017;356(6343):1112.
   PubMed Web of Science ®Google Scholar
• Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009 January;113(3):726–732.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720–724.https://doi.org/10.1073/pnas.90.2.720
   PubMed Web of Science ®Google Scholar
• Guedan S, Calderon H, Posey AD Jr., et al. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2018;12:145–156.
   PubMed Web of Science ®Google Scholar
• Alabanza L, Pegues M, Geldres C, et al. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther. 2017;25(11):2452–2465.
   PubMed Web of Science ®Google Scholar
• Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107–126.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724. https://doi.org/10.1073/pnas.90.2.720.
   PubMed Web of Science ®Google Scholar
• Lindner SE, Johnson SM, Brown CE, et al. Chimeric antigen receptor signaling: functional consequences and design implications. Sci Adv. 2020;6(21):eaaz3223–eaaz3223.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015 Aug 03; 15(8):1145–1154.
   PubMed Web of Science ®Google Scholar
• Moingeon P, Lucich JL, McConkey DJ, et al. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proceedings of the National Academy of Sciences. 1992;89(4):1492–1496.
   Google Scholar
• Roberts MR, Cooke KS, Tran AC, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998 Jul 1;161(1):375–384.
   PubMed Web of Science ®Google Scholar
• Tran AC, Zhang D, Byrn R, et al. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol. 1995 Jul 15;155(2):1000–1009.
   PubMed Web of Science ®Google Scholar
• Uherek C, Tonn T, Uherek B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002 Aug 15;100(4):1265–1273.
   PubMed Web of Science ®Google Scholar
• Müller T, Uherek C, Maki G, et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2008 Mar;57(3):411–423.
   PubMed Web of Science ®Google Scholar
• Uherek C, Müller T, Tonn T, et al. Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM. Cancer Cell Int. 2004 Jul 01; 4(1):S7.
   PubMedGoogle Scholar
• Meier R, Golovko D, Tavri S, et al. Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging. Magn Reson Med. 2011 Mar;65(3):756–763.
   PubMed Web of Science ®Google Scholar
• Tavri S, Jha P, Meier R, et al. Optical Imaging of Cellular Immunotherapy against Prostate Cancer. Mol Imaging. 2009 Jan 01;8(1):7290.2009.00002.
   PubMed Web of Science ®Google Scholar
• Esser R, Müller T, Stefes D, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med. 2012 Mar;16(3):569–581.
   PubMed Web of Science ®Google Scholar
• Seidel D, Shibina A, Siebert N, et al. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol Immunother. 2015 May;64(5):621–634.
   PubMed Web of Science ®Google Scholar
• Shiozawa M, Chang CH, Huang YC, et al. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells. BMC Immunol. 2018 Aug 3;19(1):27.
   PubMedGoogle Scholar
• Jiang H, Zhang W, Shang P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol. 2014 Mar;8(2):297–310.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Wels WS, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res. 2009 Sep;33(9):1255–1259.
   PubMed Web of Science ®Google Scholar
• Ravi D, Sarkar S, Purvey S, et al. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-Hodgkin lymphoma. Leukemia. 2020;34(5):1291–1304.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur M, Lu W, et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma. 2012 May;53(5):958–965.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur-Boissel M, Lu W, et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology. 2013 Oct 1;2(10):e26527.
   PubMed Web of Science ®Google Scholar
• Romanski A, Uherek C, Bug G, et al. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med. 2016 Jul;20(7):1287–1294.
   PubMed Web of Science ®Google Scholar
• Schirrmann T, Pecher G. Specific targeting of CD33+ leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res. 2005 Apr 01;29(3):301–306.
   PubMed Web of Science ®Google Scholar
• Wang X, Jasinski DL, Medina JL, et al. Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 2020 May 12;4(9):1950–1964.
   PubMed Web of Science ®Google Scholar
• Campbell KS, Colonna M. DAP12: a key accessory protein for relaying signals by natural killer cell receptors. Int J Biochem Cell Biol. 1999 Jun;31(6):631–636.
   PubMed Web of Science ®Google Scholar
• Töpfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. The Journal of Immunology. 2015 Apr 1;194(7):3201–3212.
   PubMed Web of Science ®Google Scholar
• Xiao L, Cen D, Gan H, et al. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. Mol Ther. 2019 Jun 5;27(6):1114–1125.
   PubMed Web of Science ®Google Scholar
• Lanier LL. DAP10- and DAP12-associated receptors in innate immunity. Immunol Rev. 2009;227(1):150–160.
   PubMedGoogle Scholar
• Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376–383.
   PubMed Web of Science ®Google Scholar
• Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013 Mar 15;73(6):1777–1786.
   PubMed Web of Science ®Google Scholar
• Wang J, Lupo KB, Chambers AM, et al. Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer. 2018 Dec 4;6(1):136.
   PubMedGoogle Scholar
• Parihar R, Rivas C, Huynh M, et al. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 Mar;7(3):363–375.
   PubMed Web of Science ®Google Scholar
• Fabian KP, Padget MR, Donahue RN, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020 May;8(1):1.
   Web of Science ®Google Scholar
• Zhang T, Scott JM, Hwang I, et al. Cutting Edge: antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency. Journal of immunology. 2013;190(4):1402–1406.
   Google Scholar
• Esensten JH, Helou YA, Chopra G, et al. CD28 Costimulation: from Mechanism to Therapy. Immunity. 2016;44(5):973–988.
   PubMed Web of Science ®Google Scholar
• Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A. 2008;105(45):17481–17486.
   PubMed Web of Science ®Google Scholar
• Liu H, Yang B, Sun T, et al. Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK-92 cells. Oncol Rep. [2015 Jan 01];33(1):95–102.
   PubMed Web of Science ®Google Scholar
• Yong CS, John LB, Devaud C, et al. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer. Oncotarget. 2016 Jun 7;7(23):34582–34598.
   PubMedGoogle Scholar
• Zhang C, Burger MC, Jennewein L, et al. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. JNCI: Journal of the National Cancer Institute. 2016 May;108(5):5.
   Google Scholar
• Pegram HJ, Jackson JT, Smyth MJ, et al. Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo. J Immunol. 2008;181(5):3449.
   PubMed Web of Science ®Google Scholar
• Wei HP, Yang N, Gu ZY, et al. [Application of Chimeric Antigen Receptor-Modified NK Cells in Multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):796–801.
   PubMedGoogle Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014 Apr;28(4):917–927.
   PubMed Web of Science ®Google Scholar
• Kim KS, Han JH, Park JH, et al. Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics. Biomaterials. 2019 Nov;221:119418.
   PubMed Web of Science ®Google Scholar
• Han J, Chu J, Keung Chan W, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep. 2015 Jul 9;5(1):11483.
   PubMedGoogle Scholar
• Genßler S, Burger MC, Zhang C, et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology. 2016 Apr;5(4):e1119354.
   PubMed Web of Science ®Google Scholar
• Chen X, Han J, Chu J, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016 May 10;7(19):27764–27777.
   PubMedGoogle Scholar
• Yu M, Luo H, Fan M, et al. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Mol Ther. 2018 Feb 7;26(2):366–378.
   PubMed Web of Science ®Google Scholar
• Smagina AS, Kulemzin SV, Yusubalieva GM, et al. VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells. Biotechnol Appl Biochem. 2020 Aug 7; 68(4):849–855.
   PubMed Web of Science ®Google Scholar
• Kim M, Pyo S, Kang CH, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PloS One. 2018;13(6):e0198347.
   PubMed Web of Science ®Google Scholar
• Reighard SD, Cranert SA, Rangel KM, et al. Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. Cell reports Medicine. 2020 Apr 21;Vol. 1(1).
   Google Scholar
• Müller S, Bexte T, Gebel V, et al. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Front Immunol. 2019;10:3123.
   PubMed Web of Science ®Google Scholar
• Gurney M, Stikvoort A, Nolan E, et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. Haematologica. 2020;12/30.
   PubMed Web of Science ®Google Scholar
• Oelsner S, Waldmann A, Billmeier A, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int J Cancer. 2019 Oct 1;145(7):1935–1945.
   PubMed Web of Science ®Google Scholar
• Mitwasi N, Feldmann A, Arndt C, et al. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep. 2020 Feb 7;10(1):2141.
   PubMed Web of Science ®Google Scholar
• Liu B, Liu ZZ, Zhou ML, et al. Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Mol Med Rep. 2019 Sep;20(3):2823–2831.
   PubMed Web of Science ®Google Scholar
• Chu Y, Hochberg J, Yahr A, et al. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. Cancer Immunol Res. 2015 Apr;3(4):333–344.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012 Aug;14(7):830–840.
   PubMed Web of Science ®Google Scholar
• Quintarelli C, Sivori S, Caruso S, et al. Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2020 Apr;34(4):1102–1115.
   PubMed Web of Science ®Google Scholar
• Wu X, Huang S. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. Bull Cancer. 2019 Nov;106(11):946–958.
   PubMed Web of Science ®Google Scholar
• Li L, Liu LN, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 2010 Mar;17(3):147–154.
   PubMed Web of Science ®Google Scholar
• Chu Y, Yahr A, Huang B, et al. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology. 2017;6(9):e1341031.
   PubMed Web of Science ®Google Scholar
• Yang S, Cao B, Zhou G, et al. Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer. Front Pharmacol. 2020;11:1089.
   PubMed Web of Science ®Google Scholar
• Jamali A, Hadjati J, Madjd Z, et al. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4. Front Immunol. 2020;11:2028.
   PubMed Web of Science ®Google Scholar
• Lee KY, Wong HY, Zeng Q, et al. Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting. Oncoimmunology. 2021 Jan 01 10(1):1877459.
   PubMedGoogle Scholar
• Suerth JD, Morgan MA, Kloess S, et al. Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med (Berl). 2016 Jan;94(1):83–93.
   PubMed Web of Science ®Google Scholar
• Herrera L, Santos S, Vesga MA, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019 Dec 10;9(1):18729.
   PubMedGoogle Scholar
• Gang M, Marin ND, Wong P, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. 2020 Nov 12;136(20):2308–2318.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang H, Ding J, et al. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. J Immunol Res. 2018;2018:4263520.
   PubMed Web of Science ®Google Scholar
• Bari R, Granzin M, Tsang KS, et al. A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy. Front Immunol. 2019;10:2001.
   PubMed Web of Science ®Google Scholar
• Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 2012 Feb;19(2):84–100.
   PubMed Web of Science ®Google Scholar
• Ingegnere T, Mariotti FR, Pelosi A, et al. Human CAR NK Cells: a New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Front Immunol. 2019;10:957.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol. 2011 Jul 01; 8(4):281–284.
   PubMed Web of Science ®Google Scholar
• Guo C, Wang X, Zhang H, et al. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells. Mol Immunol. 2019 Oct;114:108–113.
   PubMed Web of Science ®Google Scholar
• Lu C, Guo C, Chen H, et al. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis. Mol Immunol. 2020 May 6;122:200–206.
   PubMed Web of Science ®Google Scholar
• Agresta L, Hoebe KHN, Janssen EM. The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment. Front Immunol. 2018;9:2809.
   PubMed Web of Science ®Google Scholar
• Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells. Clin Cancer Res. 2009;15(15):4857.
   PubMed Web of Science ®Google Scholar
• Li Y, Hermanson DL, Moriarity BS, et al. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018 Aug 2;23(2):181–192.e5.
   PubMed Web of Science ®Google Scholar
• Mir MA. Chapter 5 - Costimulation in Lymphomas and Cancers. In: Mir MA, editor. Developing Costimulatory Molecules for Immunotherapy of Diseases. Academic Press; 2015. p. 185–254.
   Google Scholar
• Lee YE, Ju A, Choi HW, et al. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. J Control Release. 2020 Oct 10;326:310–323.
   PubMed Web of Science ®Google Scholar
• Song D-G, Ye Q, Poussin M, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119(3):696–706.
   PubMed Web of Science ®Google Scholar
• Schönfeld K, Sahm C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015 Feb;23(2):330–338.
   PubMed Web of Science ®Google Scholar
• Oelsner S, Friede ME, Zhang C, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017 Feb;19(2):235–249.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu Q, Zhong M, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019 May 16;12(1):49.
   PubMedGoogle Scholar
• Huang Y, Zeng J, Liu T, et al. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro. Cancer Manag Res. 2020;12:3247–3255.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xu J, Ding J, et al. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncol Rep. 2018 Dec;40(6):3714–3724.
   PubMed Web of Science ®Google Scholar
• Klapdor R, Wang S, Morgan M, et al. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. Int J Mol Sci. 2019 Feb 3;20(3):3.
   Web of Science ®Google Scholar
• Kobayashi E, Kishi H, Ozawa T, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Biophys Res Commun. 2014 Oct 31;453(4):798–803.
   PubMed Web of Science ®Google Scholar
• Siegler EL, Kim YJ, Chen X, et al. Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers. Mol Ther. 2017 Dec 6;25(12):2607–2619.
   PubMed Web of Science ®Google Scholar
• Oberschmidt O, Morgan M, Huppert V, et al. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering. Hum Gene Ther Methods. 2019 Jun;30(3):102–120.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhao S, Wu C, et al. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Immunotherapy. 2018 Aug;10(11):935–949.
   PubMed Web of Science ®Google Scholar
• Batchu RB, Gruzdyn OV, Tavva PS, et al. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. Surgery. 2019 Oct;166(4):503–508.
   PubMed Web of Science ®Google Scholar
• Klapdor R, Wang S, Hacker U, et al. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy. Hum Gene Ther. 2017 Oct;28(10):886–896.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Murakami T, Natsume A, et al. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells. Anticancer Res. 2020 Jun;40(6):3231–3237.
   PubMed Web of Science ®Google Scholar
• Ueda T, Kumagai A, Iriguchi S, et al. Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti–glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. Cancer Sci. 2020 May;111(5):1478–1490.
   PubMed Web of Science ®Google Scholar
• Chen KH, Wada M, Firor AE, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget. 2016 Aug 30;7(35):56219–56232.
   PubMedGoogle Scholar
• Murakami T, Nakazawa T, Natsume A, et al. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells. Anticancer Res. 2018 Sep;38(9):5049–5056.
   PubMed Web of Science ®Google Scholar
• Klöß S, Oberschmidt O, Morgan M, et al. Optimization of Human NK Cell Manufacturing: fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. Hum Gene Ther. 2017 Oct;28(10):897–913.
   PubMed Web of Science ®Google Scholar
• Kloess S, Oberschmidt O, Dahlke J, et al. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies. Hum Gene Ther. 2019 Apr;30(4):381–401.
   PubMed Web of Science ®Google Scholar
• Chen KH, Wada M, Pinz KG, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017 Oct;31(10):2151–2160.
   PubMed Web of Science ®Google Scholar
• Salman H, Pinz KG, Wada M, et al. Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells. J Cancer. 2019;10(18):4408–4419.
   PubMed Web of Science ®Google Scholar
• Yang Y, Badeti S, Tseng HC, et al. Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways. Mol Ther Methods Clin Dev. 2020 Sep 11;18:428–445.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tian K, Xu J, et al. Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma. J Immunol Res. 2017;2017:6915912.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou Y, Huang KH, et al. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. Cell Prolif. 2020 Aug;53(8):e12858.
   PubMed Web of Science ®Google Scholar
• Pinz KG, Yakaboski E, Jares A, et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 2017 Dec 22;8(68):112783–112796.
   PubMedGoogle Scholar
• Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020 Feb 18;10(1):2815.
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 Feb 6;382(6):545–553.
   PubMed Web of Science ®Google Scholar
• Chen Y, You F, Jiang L, et al. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget. 2017 Jun 6;8(23):37128–37139.
   PubMedGoogle Scholar
• Tseng HC, Xiong W, Badeti S, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020 Sep 23;11(1):4810.
   PubMed Web of Science ®Google Scholar
• Kailayangiri S, Altvater B, Spurny C, et al. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology. 2017;6(1):e1250050.
   PubMed Web of Science ®Google Scholar
• Hori T. Roles of OX40 in the Pathogenesis and the Control of Diseases. Int J Hematol. 2006 Jan 01; 83(1):17–22.
   PubMed Web of Science ®Google Scholar
• Oei VYS, Siernicka M, Graczyk-Jarzynka A, et al. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunol Res. 2018 Apr;6(4):467–480.
   PubMed Web of Science ®Google Scholar
• Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother. 2012 Sep;61(9):1451–1461.
   PubMed Web of Science ®Google Scholar
• Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 Feb;32(2):520–531.
   PubMed Web of Science ®Google Scholar
• Daher M, Basar R, Gokdemir E, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2020 Sep 9;137(5):624–636.
   PubMed Web of Science ®Google Scholar
• Colamartino ABL, Lemieux W, Bifsha P, et al. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019;10:2873.
   PubMed Web of Science ®Google Scholar
• Xia N, Haopeng P, Gong JU, et al. Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of (125)I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma. Anticancer Res. 2019 Nov;39(11):5919–5925.
   PubMed Web of Science ®Google Scholar
• Raikar SS, Fleischer LC, Moot R, et al. Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines. Oncoimmunology. 2018;7(3):e1407898.
   PubMed Web of Science ®Google Scholar
• Kulemzin SV, Gorchakov AA, Chikaev AN, et al. VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells. Oncotarget. 2018;9(10):9021–9029.
   PubMedGoogle Scholar
• Hambach J, Riecken K, Cichutek S, et al. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs). Cells. 2020 Jan 29;9:2.
   Web of Science ®Google Scholar
• Boyiadzis M, Agha M, Redner RL, et al. Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 Oct;19(10):1225–1232.
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013 Dec;15(12):1563–1570.
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625–632.
   PubMed Web of Science ®Google Scholar
• Klingemann H-G, Wong E, GJBob M, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biology of Blood and Marrow Transplantation. 1996;2(2):68–75.
   Google Scholar
• Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol. 2015;6:578.
   PubMed Web of Science ®Google Scholar
• Roberts MR, Cooke KS, Tran A-C, et al. Antigen-Specific Cytolysis by Neutrophils and NK Cells Expressing Chimeric Immune Receptors Bearing ζ or γ Signaling Domains. Journal of Immunology. 1998;161(1):375–384.
   Google Scholar
• Schnalzger TE, de Groot MH, Zhang C, et al. 3D model for CAR -mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO J. 2019 Jun 17;38(12):12.
   Web of Science ®Google Scholar
• Ao X, Yang Y, Li W, et al. Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer. J Immunother. 2019 Oct;42(8):284–296.
   PubMed Web of Science ®Google Scholar
• Nowakowska P, Romanski A, Miller N, et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother. 2018 Jan;67(1):25–38.
   PubMed Web of Science ®Google Scholar
• Kulemzin SV, Matvienko DA, Sabirov AH, et al. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines. BMC Med Genomics. 2019 Mar 13;12(Suppl S2):44.
   PubMedGoogle Scholar
• Parlar A, Sayitoglu EC, Ozkazanc D, et al. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer. Eur J Immunol. 2019 Aug;49(8):1278–1290.
   PubMed Web of Science ®Google Scholar
• Qu Y, Bi JZ. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells]. Zhonghua Yi Xue Za Zhi. 2018 Mar 20;98(11):860–866.
   PubMedGoogle Scholar
• Assaker G, Camirand A, Abdulkarim B, et al. PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease. JNCI cancer spectrum. 2020 Feb;4(1):pkz063.
   Google Scholar
• Mercogliano MF, Bruni S, Elizalde PV, et al. Tumor Necrosis Factor α Blockade: an Opportunity to Tackle Breast Cancer. Front Oncol. 2020;10:584.
   PubMed Web of Science ®Google Scholar
• Cao B, Liu M, Wang L, et al. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Biochem Biophys Res Commun. 2020 Mar 26;524(1):96–102.
   PubMed Web of Science ®Google Scholar
• Mensali N, Dillard P, Hebeisen M, et al. NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine. 2019 Feb;40:106–117.
   PubMed Web of Science ®Google Scholar
• Walseng E, Köksal H, Sektioglu IM, et al. A TCR-based Chimeric Antigen Receptor. Sci Rep. 2017 Sep 6;7(1):10713.
   PubMed Web of Science ®Google Scholar
• Meier R, Piert M, Piontek G, et al. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl Med Biol. 2008 Jul;35(5):579–588.
   PubMed Web of Science ®Google Scholar
• Chang L, Gallego-Perez D, Zhao X, et al. Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy. Lab Chip. 2015 Aug 7;15(15):3147–3153.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xu Y, Mou J, et al. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19(+) malignancy in a mouse model. Cytotherapy. 2020 Oct;22(10):552–562.
   PubMed Web of Science ®Google Scholar
• Zhang G, Liu R, Zhu X, et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol. 2013 Nov-Dec;91(10):615–624.
   PubMed Web of Science ®Google Scholar
• Müller N, Michen S, Tietze S, et al. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. J Immunother. 2015 Jun;38(5):197–210.
   PubMed Web of Science ®Google Scholar
• Kornbluth J, Flomenberg N, Dupont B. Cell surface phenotype of a cloned line of human natural killer cells. J Immunol. 1982 Dec;129(6):2831–2837.
   PubMed Web of Science ®Google Scholar
• Gunesch JT, Angelo LS, Mahapatra S, et al. Genome-wide analyses and functional profiling of human NK cell lines. Mol Immunol. 2019 Nov 01;115:64–75. https://doi.org/10.1016/j.molimm.2018.07.015.
   Google Scholar
• Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994 Apr;8(4):652–658.
   PubMed Web of Science ®Google Scholar
• Cronin J, Zhang X-Y RJ. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005;5(4):387–398.
   PubMed Web of Science ®Google Scholar
• Tam YK, Maki G, Miyagawa B, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther. 1999 May 20;10(8):1359–1373.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Cochran KJ, Cameron C, et al. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996 Feb;24(3):406–415.
   PubMed Web of Science ®Google Scholar
• Suck G, Branch DR, Smyth MJ, et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005 Oct;33(10):1160–1171.
   PubMed Web of Science ®Google Scholar
• Yodoi J, Teshigawara K, Nikaido T, et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 1985 Mar;134(3):1623–1630.
   PubMed Web of Science ®Google Scholar
• Bergman H, Sissala N, Hägerstrand H, et al. Human NK-92 Cells Function as Target Cells for Human NK Cells - Implications for CAR NK-92 Therapies. Anticancer Res. 2020 Oct;40(10):5355–5359.
   PubMed Web of Science ®Google Scholar
• Gunesch JT, Angelo LS, Mahapatra S, et al. Genome-wide analyses and functional profiling of human NK cell lines. Mol Immunol. 2019 Nov;115:64–75. https://doi.org/10.1016/j.molimm.2018.07.015
   PubMed Web of Science ®Google Scholar
• Klingemann H, Boissel L, Toneguzzo F. Natural Killer Cells for Immunotherapy – advantages of the NK-92 Cell Line over Blood NK Cells [Review]. Frontiers in Immunology. 2016 Mar 14;7:91.
   Google Scholar
• Matosevic S. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. J Immunol Res. 2018/Sep/17;2018:4054815.
   PubMed Web of Science ®Google Scholar
• Kundu S, Gurney M, O’Dwyer M. Generating natural killer cells for adoptive transfer: expanding horizons. Cytotherapy. 2021 January 08;23(7):559–566.
   PubMed Web of Science ®Google Scholar
• Li YC, Zhou Q, Song QK, et al. Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: a Cohort Study. J Immunol Res. 2020;2020:3948928.
   PubMed Web of Science ®Google Scholar
• Wilk AJ, Weidenbacher NL, Vergara R, et al. Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Adv. 2020 Sep 8;4(17):4244–4255.
   PubMed Web of Science ®Google Scholar
• Cho FN, Chang TH, Shu CW, et al. Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis. PloS One. 2014;9(10):e109352.
   PubMed Web of Science ®Google Scholar
• Herrera L, Juan M, Eguizabal C. Purification, Culture, and CD19-CAR Lentiviral Transduction of Adult and Umbilical Cord Blood NK Cells. Curr Protoc Immunol. 2020 Dec;131(1):e108.
   PubMedGoogle Scholar
• Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 2007;26(5):1423–1433.
   PubMed Web of Science ®Google Scholar
• Luevano M, Madrigal A, Saudemont A. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol. 2012;9(4):310–320.
   PubMed Web of Science ®Google Scholar
• Lowe E, Truscott LC, De Oliveira SN. In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells. Methods Mol Biol. 2016;1441:241–251.
   PubMedGoogle Scholar
• Maluski M, Ghosh A, Herbst J, et al. Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. J Clin Invest. 2019 Dec 2;129(12):5108–5122.
   PubMed Web of Science ®Google Scholar
• Gill S. Planes, Trains, and Automobiles: perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies. Curr Hematol Malig Rep. 2016;11(4):318–325.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Rozenbaum M, Meir A, Aharony Y, et al. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia [Original Research]. Frontiers in Immunology. 2020 Jul 02;11:1347.
   Google Scholar
• Merker M, Wagner J, Kreyenberg H, et al. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma [Original Research]. Frontiers in Immunology. 2020 October 19;11:2483.
   Google Scholar
• Mills JK, Henderson MA, Giuffrida L, et al. Generating CAR T cells from tumor-infiltrating lymphocytes. Ther Adv Vaccines Immunother. 2021 Jan 01;9:25151355211017119.
   Google Scholar
• Mukhopadhyay M. Macrophages enter CAR immunotherapy. Nat Methods. 2020 Jun 01; 17(6):561.
   PubMed Web of Science ®Google Scholar
• Duong CPM, Westwood JA, Yong CSM, et al. Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library Approach. PloS One. 2013;8(5):e63037.
   PubMed Web of Science ®Google Scholar